Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors

BACKGROUND: Human telomerase reverse transcriptase (hTERT) is frequently classified as a ‘universal’ tumor associated antigen due to its expression in a vast number of cancers. We evaluated plasmid DNA-encoded hTERT as an immunotherapy across nine cancer types. METHODS: A phase 1 clinical trial was...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Vonderheide, Robert H, Kraynyak, Kimberly A, Shields, Anthony F, McRee, Autumn J, Johnson, Jennifer M, Sun, Weijing, Chintakuntlawar, Ashish V, Pawlicki, Jan, Sylvester, Albert J, McMullan, Trevor, Samuels, Robert, Kim, Joseph J, Weiner, David, Boyer, Jean D, Morrow, Matthew P, Humeau, Laurent, Skolnik, Jeffrey M
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2021
Témata:
Clinical/Translational Cancer Immunotherapy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8261871/
https://ncbi.nlm.nih.gov/pubmed/34230114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-003019
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky